Literature DB >> 20569647

The well of novel antidepressants: running dry.

Pierre Blier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20569647      PMCID： PMC2895150          DOI： 10.1503/jpn.100098

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN： 1180-4882            Impact factor:   6.186


× No keyword cloud information.
  15 in total

Review 1.  Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression.

Authors:  A C Scates; P M Doraiswamy
Journal:  Ann Pharmacother       Date:  2000-11       Impact factor: 3.154

2.  Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder.

Authors:  Kasia W Lobello; Sheldon H Preskorn; Christine J Guico-Pabia; Qin Jiang; Jeffrey Paul; Alice I Nichols; Albena Patroneva; Philip T Ninan
Journal:  J Clin Psychiatry       Date:  2010-04-06       Impact factor: 4.384

3.  Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects.

Authors:  J E Turcotte; G Debonnel; C de Montigny; C Hébert; P Blier
Journal:  Neuropsychopharmacology       Date:  2001-05       Impact factor: 7.853

4.  Duloxetine for the treatment of major depressive disorder.

Authors:  Charles B Nemeroff; Alan F Schatzberg; David J Goldstein; Michael J Detke; Craig Mallinckrodt; Yili Lu; Pierre V Tran
Journal:  Psychopharmacol Bull       Date:  2002

5.  Sustained administration of bupropion alters the neuronal activity of serotonin, norepinephrine but not dopamine neurons in the rat brain.

Authors:  Mostafa El Mansari; Ramez Ghanbari; Shannon Janssen; Pierre Blier
Journal:  Neuropharmacology       Date:  2008-07-30       Impact factor: 5.250

6.  Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: a crossover study.

Authors:  Franck Chenu; Lisa A Batten; Gerald Zernig; Elisabeth Ladstaetter; Chantal Hébert; Pierre Blier
Journal:  J Clin Psychiatry       Date:  2009-07       Impact factor: 4.384

Review 7.  Catecholaminergic strategies for the treatment of major depression.

Authors:  Philippe Tremblay; Pierre Blier
Journal:  Curr Drug Targets       Date:  2006-02       Impact factor: 3.465

Review 8.  Escitalopram versus citalopram: the surprising role of the R-enantiomer.

Authors:  Connie Sánchez; Klaus P Bøgesø; Bjarke Ebert; Elin Heldbo Reines; Claus Braestrup
Journal:  Psychopharmacology (Berl)       Date:  2004-07       Impact factor: 4.530

Review 9.  Agomelatine: efficacy at each phase of antidepressant treatment.

Authors:  Sidney H Kennedy
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

10.  Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women.

Authors:  Madge R Vickers; Alastair H MacLennan; Beverley Lawton; Deborah Ford; Jeannett Martin; Sarah K Meredith; Bianca L DeStavola; Sally Rose; Anthony Dowell; Helen C Wilkes; Janet H Darbyshire; Tom W Meade
Journal:  BMJ       Date:  2007-07-11
View more
  7 in total

1.  Possible directions for the discovery of new antidepressant treatments.

Authors:  Simon N Young
Journal:  J Psychiatry Neurosci       Date:  2011-01       Impact factor: 6.186

2.  A Canadian Primary Care Sentinel Surveillance Network Study Evaluating Antidepressant Prescribing in Canada From 2006 to 2012.

Authors:  Rachael Morkem; David Barber; Tyler Williamson; Scott B Patten
Journal:  Can J Psychiatry       Date:  2015-12       Impact factor: 4.356

3.  Inflaming depression.

Authors:  Hymie Anisman
Journal:  J Psychiatry Neurosci       Date:  2011-09       Impact factor: 6.186

4.  Orphans to the rescue: orphan G-protein coupled receptors as new antidepressant targets.

Authors:  Paul R Albert
Journal:  J Psychiatry Neurosci       Date:  2020-09-01       Impact factor: 6.186

5.  Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [11C]-harmine PET study.

Authors:  Julia Sacher; Sylvain Houle; Jun Parkes; Pablo Rusjan; Sandra Sagrati; Alan A Wilson; Jeffrey H Meyer
Journal:  J Psychiatry Neurosci       Date:  2011-11       Impact factor: 6.186

Review 6.  "Novel Psychopharmacology for Depressive Disorders".

Authors:  Michele Fornaro; Domenico De Berardis; Annalisa Anastasia; Andrea Fusco
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review.

Authors:  Michele Fornaro; Domenico De Berardis; Ann Sarah Koshy; Giampaolo Perna; Alessandro Valchera; Davy Vancampfort; Brendon Stubbs
Journal:  Neuropsychiatr Dis Treat       Date:  2016-03-31       Impact factor: 2.570
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.